- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 linday 的帖子
AASLD guideline
4A. HBeAg‐POSITIVE PATIENTS WITH HIGH SERUM HBV DNA BUT NORMAL ALT (IMMUNE‐TOLERANT CHB)
These patients should be monitored at 3‐ to 6‐month intervals (Fig. 1). More frequent monitoring should be performed when ALT levels become elevated.116-119 Patients with compensated liver disease who remain HBeAg positive with HBV‐DNA levels greater than 20,000 IU/mL after a 3‐ to 6‐month period of elevated ALT levels greater than 2 times the upper limit of normal (>50 U/L for women and >70 U/L for men) should be considered for antiviral treatment.1 Liver biopsy should be considered in patients with persistent borderline normal or slightly elevated ALT levels, particularly in patients over age 40 who have been infected with HBV from a young age.120 Patients with moderate‐to‐severe inflammation (A3 or higher) and/or fibrosis (F2 or higher) can be considered for antiviral therapy.1 Noninvasive methods may be used in lieu of liver biopsies to assess for severity of fibrosis and/or inflammation.121, 122 Liver stiffness measurements (elastrography) are more accurate than serum fibrosis panels (e.g. aspartate aminotransferase [AST] to platelet ratio index or FIB‐4) in predicting significant or advanced fibrosis.123, 124 Noninvasive methods overestimate fibrosis if high levels of necroinflammation, as reflected by elevated ALT, are present.122
AASLD指南
4A。高血清HBV DNA但正常ALT(免疫耐受的CHB)的HBeAg阳性患者
这些患者应每3至6个月进行一次监测(图1)。当ALT水平升高时,应进行更频繁的监测.116-119在ALT水平升高超过3到6个月后,HBeAg阳性且HBV‐DNA水平高于20,000 IU / mL的代偿性肝病患者抗病毒治疗应考虑为正常上限的2倍(女性> 50 U / L,男性> 70 U / L)。1持续边缘性正常或ALT水平升高,特别是ALT水平升高的患者,应考虑肝活检对于40岁以上从年轻就被HBV感染的患者。120中度至重度炎症(A3或更高)和/或纤维化(F2或更高)的患者可以考虑进行抗病毒治疗。1无创方法121,122肝硬度测定(弹性成像)比血清纤维化检测更为准确(例如,天冬氨酸转氨酶[AST]与血小板比率i ndex或FIB-4)预测严重或晚期纤维化[123,124]。如果存在高水平的坏死性炎症(如ALT升高所反映),则非侵入性方法会高估纤维化程度122。 |
|